the aid library

LIST OPTIONS

Filter

9408

Tuberculosis: The connection between TB and HIV

U.S. Department of Human Services; Centers for Disease Control and Prevention (2017) C_CDC

For more information on TB or to get a TB test, call your doctor or local health department www.cdc.gov/tb/links/tboffices.htm. For further information on TB visit: CDC Division of Tuberculosis Elimination Website at www.cdc.gov/tb. Accessed November 2017

Download (178)

View PDF (225)

Introduction to HIV, AIDS and Sexually Transmitted Infection Surveillance - Surveillance of Most-At-Risk Populations (MARPS)

United States Department of Health and Human Services; Centers for Disease Control and Prevention (HHS-CDC); Global AIDS Program (GAP); et al. United States Department of Health and Human Services; Centers for Disease Control and Prevention (HHS-CDC); Global AIDS Program (GAP); et al. (2012) C2

Participant Manual September 2012 Surveillance of Populations at High Risk for HIV Transmission

Download (263)

View PDF (486)

Guidelines for screening for Tuberculosis infection and disease during the domestic medical examination for newly arrived refugees

U.S. Department of Human Services; Centers for Disease Control and Prevention; National Center for Emerging and Zoonotic Infectios Diseases (2012) C_CDC

Division of Global Migration and Quarantine April 16, 2012

Download (187)

View PDF (210)

Advocacy Guide: HIV/AIDS Prevention among injecting drug users

A. Ball; M. Beg; G. Weiler; et al. World Health Organization; UNAIDS; United Nations on Drugs and Crime (2004) C_WHO

Download (218)

View PDF (195)

Introduction to HIV, AIDS and STI Surveillance - HIV Clinical Staging and Case Reporting

Participant Manual September 2009

Download (181)

View PDF (229)

Statement of guidance and recommendations to African Union Member States on the epidemic modelling of the COVID-19 pandemic

African Union; Africa CDC Centres for Disease Control and Prevention (2021) C1

Many African countries were amongst the most rapid to respond to the emerging threat of COVID-19, implementing large-scale interventions at very early stages of their epidemic. As demonstrated in this document using very simple models, this rapid mobilization and timeliness of implementing control m... more

Download (134)

View PDF (159)

Action Protocol for Enhanced SARI and ILI Surveillance for COVID-19 in Africa

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C2

March 2020 The number of African Union Member States reporting COVID- 19 cases is increasing and there is a likelihood of community transmission. The WHO recently modified the COVID-19 suspect case definition to include severe acute respiratory infection and advises testing of all severe acute res... more

Download (396)

View PDF (959)

Extending Prevention of Mother-to-Child Transmission through Postpartum Family Planning in Lesotho

Frontiers in Reproductive Health, Family Health Department, Ministry of Health and Social Welfare, Kingdom of Lesotho (2008) C2

Download (390)

View PDF (415)

Handbook for Public Health Emergency Operations Center Operations and Management

African Union; Africa CDC Centres for Disease Control and Prevention (2021) CC

A Public Health EOC (PHEOC) serves as a hub for coordinating the preparation for, response to, and recovery from public health emergencies. The preparation includes planning, such as risk and resource mapping, development of plans and procedures, and training and exercising. The response includes al... more

Download (178)

View PDF (204)

Framework for Supply Chain Management for Public Health Emergency Preparedness and Response

African Union; Africa CDC Centres for Disease Control and Prevention (2021) CC

1 February 2021

External Link

2015 Pipeline Report HIV, Hepatitis C virus (HCV), and Tuberculosis (TB)

Polly Clayden, Simon Collins, Mike Frick, et al. A. Benzacar; HIV i-BASETREATMENT ACTION GROUP (2015)

Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development

Download (1267)

View PDF (1157)

National Technical Guidelines for Integrated Disease Surveillance and Response Liberia

Ministry of Health, Liberia, World Health Organization (WHO), and Centers for Disease Control and Prevention (CDC) (2021) C_WHO

3rd edition

Download (598)

View PDF (1071)

Efforts to Build Infection Control Capacity in in Liberia, Guinea, and Sierra Leone During the Ongoing Ebola Outbreak

Benjamin J. Park, MD; Centers for Disease Control and Prevention (CDC); Department of Health and Human Services - USA (2015) C_CDC

External Link

Buruli Ulcer Prevention of Disability (POD)
recommended

Linda Lehman, Valérie Simonet, Paul Saunderson, and Pius Agbenorku World Health Organization WHO (2006) C_WHO

This manual is for use by doctors, nurses, rehabilitation specialists, National Buruli ulcer Control Programme managers and other health workers involved in the prevention of disability activities in Buruli ulcer. You can download chapters and presentations

Download (113)

View PDF (156)

Trend of HIV/AIDS for the last 26 years andpredicting achievement of the 90–90-90 HIV prevention targets by 2020 in Ethiopia:a time series analysis

Girum T., Wasie A. and Worku A. (2018) C1

Download (554)

View PDF (280)

Module 4: Essential Components of Antenatal Care and Emergency Obstetric Care

Fistula Care; USAID; Engender Health; et al. (2020) C1

Prevention and Recognition of Obstetric Fistula Training Package Accessed on 2 September 2020

Download (1006)

View PDF (1902)

HIV and TB in Practice for nurses: Pregnancy and TB/HIV

Lesley Odendal (2013) C1

HIV & AIDS Treatment in Practice Issue 203

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (815)

View PDF (1855)

HIV and TB in Practice for nurses: TB infection control

Lesley Odendal (2013) C1

HIV & AIDS Treatment in Practice no. 201

Download (195)

View PDF (207)

Maintaining and improving quality of care within HIV clinical services - Technical Brief

World Health Organization (2019) C_WHO

HIV Treatment

Buruli Ulcer Prevention of Disability (POD) recommended

Buruli Ulcer Prevention of Disability (POD)
recommended